×




NICE or Nasty? Access and Reimbursement of Multiple Sclerosis Medicines in the UK Net Present Value (NPV) / MBA Resources

Introduction to Net Present Value (NPV) - What is Net Present Value (NPV) ? How it impacts financial decisions regarding project management?

NPV solution for NICE or Nasty? Access and Reimbursement of Multiple Sclerosis Medicines in the UK case study


At Oak Spring University, we provide corporate level professional Net Present Value (NPV) case study solution. NICE or Nasty? Access and Reimbursement of Multiple Sclerosis Medicines in the UK case study is a Harvard Business School (HBR) case study written by Reinhard Angelmar, Andrea Bieser. The NICE or Nasty? Access and Reimbursement of Multiple Sclerosis Medicines in the UK (referred as “Sclerosis Nice” from here on) case study provides evaluation & decision scenario in field of Sales & Marketing. It also touches upon business topics such as - Value proposition, Technology.

The net present value (NPV) of an investment proposal is the present value of the proposal’s net cash flows less the proposal’s initial cash outflow. If a project’s NPV is greater than or equal to zero, the project should be accepted.

NPV = Present Value of Future Cash Flows LESS Project’s Initial Investment






Case Description of NICE or Nasty? Access and Reimbursement of Multiple Sclerosis Medicines in the UK Case Study


NICE (National Institute for Health and Clinical Excellence) reviews the cost effectiveness of medicines for the treatment of multiple sclerosis (annual cost per patient 10,000-18,000) and does not authorize their use within the UK National Health Service. However, an agreement between the manufacturers and the Department of Health is reached on an innovative risk sharing scheme.


Case Authors : Reinhard Angelmar, Andrea Bieser

Topic : Sales & Marketing

Related Areas : Technology




Calculating Net Present Value (NPV) at 6% for NICE or Nasty? Access and Reimbursement of Multiple Sclerosis Medicines in the UK Case Study


Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 6 %
Discounted
Cash Flows
Year 0 (10020261) -10020261 - -
Year 1 3465512 -6554749 3465512 0.9434 3269351
Year 2 3960680 -2594069 7426192 0.89 3524991
Year 3 3943460 1349391 11369652 0.8396 3311005
Year 4 3251416 4600807 14621068 0.7921 2575426
TOTAL 14621068 12680773




The Net Present Value at 6% discount rate is 2660512

In isolation the NPV number doesn't mean much but put in right context then it is one of the best method to evaluate project returns. In this article we will cover -

Different methods of capital budgeting


What is NPV & Formula of NPV,
How it is calculated,
How to use NPV number for project evaluation, and
Scenario Planning given risks and management priorities.




Capital Budgeting Approaches

Methods of Capital Budgeting


There are four types of capital budgeting techniques that are widely used in the corporate world –

1. Payback Period
2. Net Present Value
3. Profitability Index
4. Internal Rate of Return

Apart from the Payback period method which is an additive method, rest of the methods are based on Discounted Cash Flow technique. Even though cash flow can be calculated based on the nature of the project, for the simplicity of the article we are assuming that all the expected cash flows are realized at the end of the year.

Discounted Cash Flow approaches provide a more objective basis for evaluating and selecting investment projects. They take into consideration both –

1. Timing of the expected cash flows – stockholders of Sclerosis Nice have higher preference for cash returns over 4-5 years rather than 10-15 years given the nature of the volatility in the industry.
2. Magnitude of both incoming and outgoing cash flows – Projects can be capital intensive, time intensive, or both. Sclerosis Nice shareholders have preference for diversified projects investment rather than prospective high income from a single capital intensive project.






Formula and Steps to Calculate Net Present Value (NPV) of NICE or Nasty? Access and Reimbursement of Multiple Sclerosis Medicines in the UK

NPV = Net Cash In Flowt1 / (1+r)t1 + Net Cash In Flowt2 / (1+r)t2 + … Net Cash In Flowtn / (1+r)tn
Less Net Cash Out Flowt0 / (1+r)t0

Where t = time period, in this case year 1, year 2 and so on.
r = discount rate or return that could be earned using other safe proposition such as fixed deposit or treasury bond rate. Net Cash In Flow – What the firm will get each year.
Net Cash Out Flow – What the firm needs to invest initially in the project.

Step 1 – Understand the nature of the project and calculate cash flow for each year.
Step 2 – Discount those cash flow based on the discount rate.
Step 3 – Add all the discounted cash flow.
Step 4 – Selection of the project

Why Sales & Marketing Managers need to know Financial Tools such as Net Present Value (NPV)?

In our daily workplace we often come across people and colleagues who are just focused on their core competency and targets they have to deliver. For example marketing managers at Sclerosis Nice often design programs whose objective is to drive brand awareness and customer reach. But how that 30 point increase in brand awareness or 10 point increase in customer touch points will result into shareholders’ value is not specified.

To overcome such scenarios managers at Sclerosis Nice needs to not only know the financial aspect of project management but also needs to have tools to integrate them into part of the project development and monitoring plan.

Calculating Net Present Value (NPV) at 15%

After working through various assumptions we reached a conclusion that risk is far higher than 6%. In a reasonably stable industry with weak competition - 15% discount rate can be a good benchmark.



Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 15 %
Discounted
Cash Flows
Year 0 (10020261) -10020261 - -
Year 1 3465512 -6554749 3465512 0.8696 3013489
Year 2 3960680 -2594069 7426192 0.7561 2994843
Year 3 3943460 1349391 11369652 0.6575 2592889
Year 4 3251416 4600807 14621068 0.5718 1859008
TOTAL 10460228


The Net NPV after 4 years is 439967

(10460228 - 10020261 )








Calculating Net Present Value (NPV) at 20%


If the risk component is high in the industry then we should go for a higher hurdle rate / discount rate of 20%.

Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 20 %
Discounted
Cash Flows
Year 0 (10020261) -10020261 - -
Year 1 3465512 -6554749 3465512 0.8333 2887927
Year 2 3960680 -2594069 7426192 0.6944 2750472
Year 3 3943460 1349391 11369652 0.5787 2282095
Year 4 3251416 4600807 14621068 0.4823 1568005
TOTAL 9488499


The Net NPV after 4 years is -531762

At 20% discount rate the NPV is negative (9488499 - 10020261 ) so ideally we can't select the project if macro and micro factors don't allow financial managers of Sclerosis Nice to discount cash flow at lower discount rates such as 15%.





Acceptance Criteria of a Project based on NPV

Simplest Approach – If the investment project of Sclerosis Nice has a NPV value higher than Zero then finance managers at Sclerosis Nice can ACCEPT the project, otherwise they can reject the project. This means that project will deliver higher returns over the period of time than any alternate investment strategy.

In theory if the required rate of return or discount rate is chosen correctly by finance managers at Sclerosis Nice, then the stock price of the Sclerosis Nice should change by same amount of the NPV. In real world we know that share price also reflects various other factors that can be related to both macro and micro environment.

In the same vein – accepting the project with zero NPV should result in stagnant share price. Finance managers use discount rates as a measure of risk components in the project execution process.

Sensitivity Analysis

Project selection is often a far more complex decision than just choosing it based on the NPV number. Finance managers at Sclerosis Nice should conduct a sensitivity analysis to better understand not only the inherent risk of the projects but also how those risks can be either factored in or mitigated during the project execution. Sensitivity analysis helps in –

What can impact the cash flow of the project.

What will be a multi year spillover effect of various taxation regulations.

What are the uncertainties surrounding the project Initial Cash Outlay (ICO’s). ICO’s often have several different components such as land, machinery, building, and other equipment.

What are the key aspects of the projects that need to be monitored, refined, and retuned for continuous delivery of projected cash flows.

Understanding of risks involved in the project.

Some of the assumptions while using the Discounted Cash Flow Methods –

Projects are assumed to be Mutually Exclusive – This is seldom the came in modern day giant organizations where projects are often inter-related and rejecting a project solely based on NPV can result in sunk cost from a related project.

Independent projects have independent cash flows – As explained in the marketing project – though the project may look independent but in reality it is not as the brand awareness project can be closely associated with the spending on sales promotions and product specific advertising.






Negotiation Strategy of NICE or Nasty? Access and Reimbursement of Multiple Sclerosis Medicines in the UK

References & Further Readings

Reinhard Angelmar, Andrea Bieser (2018), "NICE or Nasty? Access and Reimbursement of Multiple Sclerosis Medicines in the UK Harvard Business Review Case Study. Published by HBR Publications.


AIT Therapeutics SWOT Analysis / TOWS Matrix

Financial , Misc. Financial Services


Hybrid Energy Holdin SWOT Analysis / TOWS Matrix

Financial , Misc. Financial Services


Hite Jinro SWOT Analysis / TOWS Matrix

Consumer/Non-Cyclical , Beverages (Alcoholic)


Nusantara Inti Corpora SWOT Analysis / TOWS Matrix

Consumer Cyclical , Textiles - Non Apparel


Lingkaran Trans Kota SWOT Analysis / TOWS Matrix

Transportation , Misc. Transportation


Nabaltec SWOT Analysis / TOWS Matrix

Basic Materials , Chemical Manufacturing


Seikagaku Corp SWOT Analysis / TOWS Matrix

Healthcare , Biotechnology & Drugs


II-VI SWOT Analysis / TOWS Matrix

Technology , Scientific & Technical Instr.


Toyobo SWOT Analysis / TOWS Matrix

Basic Materials , Fabricated Plastic & Rubber